Countries covered by the agreement include Japan, South Korea, China, Taiwan and Singapore and the licensing agreement provides for, among other things, equity payments, milestone payments and double digit royalties on sales of Myodur in the Pacific Rim.
“We are looking forward to bringing Myodur to muscular dystrophy patients in the Pacific Rim as quickly as possible,” commented JCR’s CEO, Shin Ashida. “JCR shares a similar philosophy with CepTor of bringing meaningful products to market for unmet medical needs. Muscular dystrophy represents one of the gravest needs where there is no current definitive therapy. We are very excited about this partnership.”
CepTor’s primary efforts are currently being focused on moving Myodur into phase I/II clinical trials for Duchenne’s muscular dystrophy, as well as continuing with development of products for multiple sclerosis, retinal degeneration and epilepsy.